| The following article features coverage from the American Urological Association (AUA) 2019 meeting. Click here to read more of Renal & Urology News’ conference coverage. |
CHICAGO—Investigators at Memorial Sloan Kettering Cancer Center (MSKCC) in New York found that surgical and oncologic outcomes of patients who underwent radical cystectomy for bladder cancer at the institution have improved over a 21-year period, according to a presentation at the 2019 American Urological Association annual meeting.
Nima Almassi, MD, and collaborators identified a cohort of 2911 patients who underwent RC for urothelial carcinoma of the bladder from 1995 to 2015. Patients had a median follow-up of 5.7 years. Neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer (MIBC) increased significantly from less than 6% of patients before 2000 to 57% from 2010 to 2015, with a corresponding increase in pT0 rates among patients with MIBC, with 22% of all patients receiving NAC demonstrating a complete pathologic response (pT0N0), Dr Almassi reported.
Additionally, the mean lymph node (LN) yield increased significantly from a mean of 7 LNs in 1995 to 24 in 2015. Positive soft tissue and urothelial margin rates decreased from 10% and 14% to 2% and 10%, respectively, from 1995 to 2015.
The 5-year probabilities of disease recurrence and cancer-specific death decreased from peaks of 42% and 35%, respectively, in 1998 to 34% and 25%, respectively, by the end of the study.
Read more of Renal & Urology News’ coverage of the AUA 2019 meeting by visiting the conference page.
Reference
Almassi N, Cha E, Vertosick E, et al. Surgical and oncologic outcomes in patients undergoing radical cystectomy from 1995-2015: The Memorial Sloan Kettering Experience. Presented at the 2019 American Urological Association annual meeting held May 3-6 in Chicago. Abstract PD47-04.
